Alka Batycky - 30 May 2023 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Director
Signature
/s/ Gregory Oakes, attorney-in-fact
Issuer symbol
N/A
Transactions as of
30 May 2023
Net transactions value
$0
Form type
4
Filing time
01 Jun 2023, 16:21:51 UTC
Next filing
23 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +3,600 $0.000000 3,600 30 May 2023 Common Stock 3,600 $3.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying the option will vest and become exercisable in 36 equal monthly installments beginning on May 30, 2023, subject to the Reporting Person's continuous service with the Issuer on each such date.